Early pre-clinical studies have shown that EGFR-sensitive mutation could increase the expressions of PD-1, PD-L1, and CTLA-4 through the P-ErK1/2P-C-Jun signaling pathway and accelerate the apoptosis of T cells in the TME (Akbay et al., 2013; Chen et al., 2015; Ota et al., 2015), which induce the immune escape of tumor cells, suppressing the body’s own immune function. This evidence concerns the gene EGFR and neoplasm.